Organon &

Organon & Goodwill

The Goodwill of Organon & (OGN) as of Oct 23, 2026 is 4.15 B USD. In the previous year, Goodwill was 4.68 B USD — a change of -11.26% (lower).

Goodwill

4.15 BUSD

YoY

-11.26%

Last updated:

Goodwill of Organon & is 2025 4.15 B USD. Goodwill of Organon & was 2024 4.68 B USD. It decreases by -11.26% lower compared to the previous year.

The Organon & Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2018
4.60 B USD
Jan 1, 2019
4.60 B USD
Jan 1, 2020
4.60 B USD
Jan 1, 2021
4.60 B USD
Jan 1, 2022
4.60 B USD
Jan 1, 2023
4.60 B USD
Jan 1, 2024
4.68 B USD
Jan 1, 2025
4.15 B USD
The Organon & Goodwill history
YEARGoodwillYoY
4.15 BUSD-11.26%
4.68 BUSD+1.67%
4.60 BUSD0.00%
4.60 BUSD0.00%
4.60 BUSD0.00%
4.60 BUSD0.00%
4.60 BUSD0.00%
4.60 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Organon & stock

Goodwill of Organon & is 4.15 B USD in 2025.

Goodwill of Organon & changed from 4.68 B USD to 4.15 B USD, representing a -11.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Organon & since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Organon & historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Organon &

All Key Metrics — Organon &